Compare
CRDF 10-KFeb 24 '26
“In August 2023, we announced that Pfizer Ignite, a new end-to-end service for biotech companies, will be responsible for the clinical activities of our new CRDF-004 trial in first-line RAS-mutated mCRC.”
CRBU 10-KMar 5 '26
“Pfizer, related party (1) 2,487 2,487 —”